Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Efficacy and Mechanism of Action of Novel Nucleoside Analogues Against Solid Tumours

EF 2014-15

Résumé
Despite remarkable research efforts and advances, an effective treatment for various gastrointestinal cancers including pancreatic and liver cancer remains a major clinical challenge. Nucleoside analogues (NA) are a class of potent antitumour agents known as antimetabolites. Gemcitabine and 5-Fluorouracil (5-FU) among many others are potent chemotherapeutic agents; however, significant drug resistances, poor bioavailability and toxicity have been noticed. The development of new drugs, namely a new class of NAs with a different mechanism of action than antimetabolites is the objective of our research program. Over the past few years, we have successfully synthesized new chemical entities that represent a novel class of NAs with dual prodrug potential. These molecules have an all-carbon quaternary stereogenic center and were never prepared before due to synthetic challenges associated with generating all-carbon quaternary centers on such complex molecules. By introducing this modification, the NAs can be locked in a conformation that increases molecular recognition and stability to various catabolic mechanisms. BxPC3 (pancreatic cancer) and HepG2 (liver cancer) cells were treated with the molecules and cellular viability was assessed. Members of these families have demonstrated activity in the cancer cell lines at the micromolar level and the active molecules have shown matching or better activities than 5-FU and Gemcitabine. The mechanism of action of these proprietary molecules is currently under investigation with the hypothesis that they target two distinct metabolic processes critical to cancer cell survival: nucleic acid synthesis and mitochondrial bioenergetic metabolism.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331246
Name
Rostami Ariana
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Efficacy and Mechanism of Action of Novel Nucleoside Analogues Against Solid Tumours
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apoptosis; Cell Proliferation And Viability; Chemotherapeutic Agents; Drug Development; Liver Cancer; Mechanism Of Action; Mitochondrial Metabolism; Nucleoside Analogues; Pancreatic Cancer; Synergy
Abstract
Despite remarkable research efforts and advances, an effective treatment for various gastrointestinal cancers including pancreatic and liver cancer remains a major clinical challenge. Nucleoside analogues (NA) are a class of potent antitumour agents known as antimetabolites. Gemcitabine and 5-Fluorouracil (5-FU) among many others are potent chemotherapeutic agents; however, significant drug resistances, poor bioavailability and toxicity have been noticed. The development of new drugs, namely a new class of NAs with a different mechanism of action than antimetabolites is the objective of our research program. Over the past few years, we have successfully synthesized new chemical entities that represent a novel class of NAs with dual prodrug potential. These molecules have an all-carbon quaternary stereogenic center and were never prepared before due to synthetic challenges associated with generating all-carbon quaternary centers on such complex molecules. By introducing this modification, the NAs can be locked in a conformation that increases molecular recognition and stability to various catabolic mechanisms. BxPC3 (pancreatic cancer) and HepG2 (liver cancer) cells were treated with the molecules and cellular viability was assessed. Members of these families have demonstrated activity in the cancer cell lines at the micromolar level and the active molecules have shown matching or better activities than 5-FU and Gemcitabine. The mechanism of action of these proprietary molecules is currently under investigation with the hypothesis that they target two distinct metabolic processes critical to cancer cell survival: nucleic acid synthesis and mitochondrial bioenergetic metabolism.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rostami, Ariana
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~